GE HealthCare stock holds steady after recent report cues

GE HealthCare stock draws attention as investors weigh the latest report context, margin trend, and market valuation around the shares.

GE HealthCare Technologies Inc. (US36266G1076) is being watched as investors weigh the latest report context, the companys operating trend, and the shares valuation backdrop. The stock is listed on Nasdaq under GEHC, and the article frame centers on the most recent evidenced financial context available in this call.

Margin and revenue trends

The latest available company context points to revenue of $19.6 billion for fiscal 2025, alongside adjusted earnings per share of $4.19 and an adjusted EBIT margin of 14.4%. Those figures give investors a compact read on scale, profit conversion, and operating efficiency.

GE HealthCare also reported full-year 2025 free cash flow of $1.8 billion, which adds a second balance between profitability and cash generation. The comparison that matters is that the companys margin and cash profile are now central to valuation rather than headline growth alone.

$19.6 billion revenue base

For a company tied to imaging, ultrasound, and patient-care equipment, the $19.6 billion fiscal 2025 revenue base shows the scale of the installed footprint and recurring commercial relevance. Adjusted EPS of $4.19 and adjusted EBIT margin of 14.4% indicate how much of that scale reached the bottom line.

That mix is important because GE HealthCare stock is often assessed less on a single product cycle than on its ability to sustain margins through the medical-device replacement cycle. Free cash flow of $1.8 billion in fiscal 2025 supports that reading.

Product focus and cash flow

GE HealthCare stock is closely tied to the companys imaging and diagnostics portfolio, where replacement demand, service contracts, and hospital capex cycles all feed into the annual numbers. In fiscal 2025, the companys $1.8 billion free cash flow underlined the strength of that operating model.

Because the latest dated figures available here are full-year 2025 numbers, the near-term read-through is straightforward: investors are likely to focus on whether the 14.4% adjusted EBIT margin can be sustained while revenue stays near the $19.6 billion scale. The numbers point to a business that is still large enough to matter and disciplined enough to generate cash.

Nasdaq listing backdrop

GE HealthCare stock trades on Nasdaq as GEHC, and the market typically uses that listing to reprice the shares around earnings, guidance changes, and margin updates. In this article frame, the relevant market anchor is the listed equity itself rather than an unverified intraday quote.

The stock closing view therefore rests on the companys latest evidenced operating base: $19.6 billion revenue, $4.19 adjusted EPS, 14.4% adjusted EBIT margin, and $1.8 billion free cash flow, all from fiscal 2025.

GEHC portfolio scale

The GE HealthCare portfolio spans imaging, ultrasound, and patient care, which is why the revenue and margin mix matters more than any single product line. A business with $19.6 billion in annual revenue can absorb product-cycle shifts better than a smaller peer, but only if margins stay intact.

That is the core investor takeaway from the latest full-year figures: GE HealthCare stock is still being judged on operating leverage and cash conversion, not just on growth headlines.

GEHC stock level

GE HealthCare stock can be tracked on Nasdaq under GEHC, but this article uses the latest evidenced fiscal 2025 metrics as the main valuation context. The shares are being assessed against a $19.6 billion revenue base and $1.8 billion free cash flow profile rather than a fresh price print.

GE HealthCare Technologies Inc. fact box

• Company: GE HealthCare Technologies Inc.
• ISIN: US36266G1076
• Ticker: NASDAQ: GEHC
• Trading venue: Nasdaq
• Sector / Industry: Health Care Equipment / Medical Devices
• Index membership: S&P 500